Laser Optoacoustic and Ultrasonic Imaging System Assembly in Finding Changes in Tumors in Patients With Breast Cancer

NCT ID: NCT01755130

Last Updated: 2021-06-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-05-13

Study Completion Date

2021-06-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial studies laser optoacoustic and ultrasonic imaging system assembly in finding changes in tumors in patients with breast cancer. Diagnostic procedures, such as laser optoacoustic and ultrasonic imaging system assembly, may help find and diagnose breast cancer and find out how far the disease has spread.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To successfully obtain images from laser optoacoustic and ultrasonic imaging system assembly (LOUISA) 3-dimensional (3D) and assess pathology in order to guide image calibration and gain knowledge about LOUISA 3D capabilities to detect and differentiate breast tumors.

II. Estimate and compare the false positive rate of LOUISA-3D compared to standard of care ultrasound for detecting breast cancer in year 5 of the study.

SECONDARY OBJECTIVES:

I. Determine optimal scanning parameters by assessing certain machine parameters (e.g. illumination and detection conditions, laser pulse repetition rate, laser ultrasound emission characteristics, type of imaging probe, two-dimensional images vs three-dimensional images, coupling medium characteristics, software and firmware, etc.), anatomical information (speed of sound image, acoustic attenuation image, acoustic scattering image), and functional information (total hemoglobin distribution \[THb\]/image of angiogenesis density, image of blood oxygen saturation \[SO2\], and image of water distribution).

OUTLINE:

Patients undergo LOUISA 3D over approximately 30 minutes on the same day or within 7 days of any breast imaging procedure and within 7 days before biopsy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Neoplasm Inflammatory Breast Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diagnostic (LOUISA 3D)

Patients undergo LOUISA 3D over approximately 30 minutes on the same day or within 7 days of any breast imaging procedure and within 7 days before biopsy.

Group Type EXPERIMENTAL

Photoacoustic Imaging

Intervention Type PROCEDURE

Undergo LOUISA 3D

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Photoacoustic Imaging

Undergo LOUISA 3D

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Mass palpable or nonpalpable
* Tissue density - all tissue types
* Menses - any stage of cycle
* Suspicious breast mass(es) defined by mammography or ultrasound indicating biopsy is needed (biopsy not needed if previous biopsy results are available on target lesion\[s\])
* Tumor location - the mammography or ultrasound report should not say that the tumor is in close proximity of chest wall
* Any tumor type (patients with inflammatory breast cancer may be included)

Exclusion Criteria

* Patient is unable or unwilling to give informed consent for any reason
* Disability (psychiatric, neurological or physical, which precludes examination)
* Patient has tattoos on the region of interest
* Overweight over 250 pounds (LB)
* Very large breast size exceeding 6 inch diameter
* Patient has body piercing jewelry through the nipple that cannot be removed
* Patient has had a core or excisional biopsy in the ipsilateral breast within the last 2 weeks (patients with previous fine needle aspirations but no ultrasound evidence of hematoma or post biopsy \[bx\] change may be included)
* Patient has inflammatory skin disease (i.e., psoriasis, eczema) or other irritation affecting the breast
* Patient has any pain or high sensitivity in the breast
* Currently taking hormonal replacement therapy
* Non-ambulatory or unable to comply with exam
* Pregnant (pregnancy test is not required, only as confirmed by patient)
* Breastfeeding
* Prior breast treatment for target lesion
* Previous surgery of the breast in the last 3 months
Minimum Eligible Age

20 Years

Maximum Eligible Age

85 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

M.D. Anderson Cancer Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wei Yang

Role: PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

M D Anderson Cancer Center

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

http://www.mdanderson.org

University of Texas MD Anderson Cancer Center Website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2014-01243

Identifier Type: REGISTRY

Identifier Source: secondary_id

NCI-2013-00149

Identifier Type: -

Identifier Source: secondary_id

2012-0210

Identifier Type: OTHER

Identifier Source: secondary_id

2012-0210

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Using Diagnostic Tools to Stage Breast Cancer
NCT00367666 ACTIVE_NOT_RECRUITING NA
3D Ultrasound Breast Imaging
NCT04692818 RECRUITING NA